Palvella Therapeutics (NASDAQ:PVLA - Get Free Report) is expected to be releasing its earnings data before the market opens on Monday, March 31st. Analysts expect Palvella Therapeutics to post earnings of ($0.39) per share for the quarter.
Palvella Therapeutics Price Performance
NASDAQ PVLA traded up $0.37 during trading on Friday, reaching $28.13. The company's stock had a trading volume of 29,988 shares, compared to its average volume of 61,370. The company has a 50 day moving average of $19.95. Palvella Therapeutics has a 12 month low of $6.20 and a 12 month high of $29.27. The stock has a market cap of $315.65 million, a price-to-earnings ratio of -2.32 and a beta of 0.54.
Wall Street Analyst Weigh In
Several research firms recently weighed in on PVLA. HC Wainwright reaffirmed a "buy" rating and set a $38.00 price objective on shares of Palvella Therapeutics in a research report on Tuesday, February 11th. TD Cowen began coverage on shares of Palvella Therapeutics in a report on Wednesday, February 5th. They issued a "buy" rating and a $44.00 target price for the company. Stifel Nicolaus began coverage on shares of Palvella Therapeutics in a report on Wednesday. They set a "buy" rating and a $45.00 price target on the stock. Jones Trading started coverage on shares of Palvella Therapeutics in a research report on Tuesday. They issued a "buy" rating and a $45.00 target price on the stock. Finally, Scotiabank initiated coverage on Palvella Therapeutics in a research note on Friday, March 7th. They issued a "sector outperform" rating and a $50.00 price target for the company. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Palvella Therapeutics currently has an average rating of "Buy" and an average target price of $43.50.
Get Our Latest Stock Report on PVLA
About Palvella Therapeutics
(
Get Free Report)
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.
See Also
Before you consider Palvella Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Palvella Therapeutics wasn't on the list.
While Palvella Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
